[Heart involvement in systemic sclerosis]

Area of Science:

• Cardiology
• Rheumatology
• Vascular Biology

Background:

• Primary myocardial involvement is frequent in systemic sclerosis.
• Cardiac involvement, particularly myocardial fibrosis from ischemic injury, is a poor prognostic indicator.
• Microcirculatory impairment and abnormal vasoreactivity are implicated in the pathogenesis of cardiac dysfunction.

Purpose of the Study:

• To elucidate the mechanisms of cardiac involvement in systemic sclerosis.
• To highlight the prognostic significance of cardiac manifestations.
• To review current treatment strategies for myocardial involvement.

Main Methods:

• Review of existing evidence on cardiac involvement in systemic sclerosis.
• Analysis of pathological mechanisms including microcirculatory impairment and fibrosis.
• Evaluation of clinical outcomes and treatment efficacy.

Main Results:

• Myocardial fibrosis due to repeated focal ischemic injury is a key feature.
• Pericardial and conduction system abnormalities are common but often asymptomatic or non-serious.
• Arrhythmias can be life-threatening, while valvular involvement is minimal.
• Calcium channel blockers and ACE inhibitors are primary treatment modalities.

Conclusions:

• Cardiac involvement in systemic sclerosis, primarily myocardial fibrosis, significantly impacts prognosis.
• Management requires addressing microcirculatory dysfunction and utilizing specific pharmacotherapies.
• Long-term treatment with vasodilators is essential for patients with systemic sclerosis and cardiac involvement.